2m 2m 2m 2m 2m 2m 2m
IMMUNOVANT (IMVT)
NASDAQ
$37.39-$0.71 (-1.86%)
Price as of Jun 23, 2026 7:07 PM EDT- $7.8BMarket Cap
- 146.28%1-Year Change
- BiotechnologyIndustry
IMMUNOVANT (IMVT)
$37.39-$0.71 (-1.86%)
Annual
Quarterly
03/31/2026 | 03/31/2025 | 03/31/2024 | 03/31/2023 | ||
|---|---|---|---|---|---|
Income Statement | |||||
Total Operating Revenue | N/A N/A | N/A N/A | 24.9M +229.22% | 7.6M N/A | |
Cost of Revenue | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Gross Profit | 0 N/A | 0 -100.00% | 24.9M +229.22% | 7.6M N/A | |
Sales and Marketing Expense | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Research and Development Expense | -456.7M +26.53% | -360.9M +69.50% | -212.9M +25.06% | -170.3M +67.23% | |
Depreciation and Amortization Expense | 409,000 +8.49% | 377,000 +63.20% | 231,000 +19.69% | 193,000 +53.17% | |
Total Operating Expenses | 532.9M +21.62% | 438.2M +54.98% | 282.7M +29.52% | 218.3M +39.89% | |
Operating Profit | -505.4M +22.39% | -412.9M +59.58% | -258.8M +22.67% | -211.0M +34.52% | |
Interest Income | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Interest Expense | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Interest Income and Expense and Net | 0 N/A | 0 N/A | 0 N/A | 0 N/A | |
Total Nonoperating Income and Expense | 2.2M +363.06% | 471,000 +146.73% | -1.0M +298.42% | -253,000 -67.61% | |
Income before Taxes | -505.4M +22.39% | -412.9M +59.58% | -258.8M +22.67% | -211.0M +34.52% | |
Income Taxes | 215,000 -75.87% | 891,000 +57.14% | 567,000 +6,200.00% | 9,000 +110.71% | |
Extraordinary Items | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Net Income | -505.6M +22.17% | -413.8M +59.58% | -259.3M +22.93% | -211.0M +34.60% | |
Net Income from Continuing Operations Applicable to Common | -505.4M +22.39% | -412.9M +59.58% | -258.8M +22.67% | -211.0M +34.52% | |
Basic EPS and Net Income | -2.77 +1.47% | -2.73 +45.21% | -1.88 +9.94% | -1.71 +19.58% | |
Diluted EPS and Net Income | -2.77 +1.47% | -2.73 +45.21% | -1.88 +9.94% | -1.71 +19.58% | |
Basic Weighted Average Shares | 182.4M +20.35% | 151.6M +9.76% | 138.1M +12.21% | 123.1M +12.21% | |
Diluted Weighted Average Shares | 182.4M +20.35% | 151.6M +9.76% | 138.1M +12.21% | 123.1M +12.21% | |
Balance Sheet | |||||
Cash and Cash Equivalents | 902.1M +26.35% | 714.0M +12.37% | 635.4M +68.74% | 376.5M -23.75% | |
Short-Term Investments | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash and Cash Equivalents and Short-Term Investments | 902.1M +26.35% | 714.0M +12.37% | 635.4M +68.74% | 376.5M -23.75% | |
Total Current Assets | 948.8M +23.60% | 767.7M +15.30% | 665.8M +64.66% | 404.3M -21.17% | |
Accumulated Depreciation | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Property and Plant and Equipment and Net | 443,000 -47.51% | 844,000 +82.68% | 462,000 +38.74% | 333,000 +0.91% | |
Total Long-Term Assets | 7.7M +0.81% | 7.6M +1,548.92% | 462,000 +38.74% | 333,000 +0.91% | |
Total Assets | 957.0M +23.29% | 776.2M +16.49% | 666.4M +64.19% | 405.8M -21.28% | |
Income Taxes Payable | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Short-Term Debt | N/A N/A | N/A N/A | N/A N/A | 350,000 +104.68% | |
Total Current Liabilities | 104.4M +51.83% | 68.8M +41.49% | 48.6M +12.27% | 43.3M -2.75% | |
Total Long-Term Debt | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Long-Term Liabilities | N/A N/A | N/A N/A | 0 -100.00% | 47,000 -96.14% | |
Total Liabilities | 104.4M +51.83% | 68.8M +41.49% | 48.6M +12.14% | 43.3M -5.24% | |
Retained Earnings | -1.7B +40.79% | -1.2B +50.12% | -825.7M +45.79% | -566.3M +59.36% | |
Total Stockholders Equity | 852.6M +20.52% | 707.4M +14.52% | 617.8M +70.42% | 362.5M -22.84% | |
Total Shares Outstanding | 203.9M +19.89% | 170.1M +16.85% | 145.6M +11.70% | 130.3M +11.89% | |
Cash Flow | |||||
Cash from Operating Activities | -407.3M +8.36% | -375.9M +75.46% | -214.2M +13.83% | -188.2M +77.35% | |
Capital Expenditures | 8,000 -98.95% | 759,000 +110.83% | 360,000 +82.74% | 197,000 -22.44% | |
Cash from Investing Activities | -8,000 -98.95% | -759,000 +110.83% | -360,000 +82.74% | -197,000 -22.44% | |
Dividends Paid | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash from Financing Activities | 595.8M +31.08% | 454.5M -3.80% | 472.4M +566.47% | 70.9M -64.58% | |
Financials Ratio | |||||
Gross Margin | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Operating Margin | N/A N/A | N/A N/A | -1,037.23% -62.74% | -2,783.73% N/A | |
Return on Assets | -58.34% +1.69% | -57.37% +18.61% | -48.37% +5.64% | -45.79% +35.57% | |
Return on Equity | -64.82% +3.78% | -62.46% +18.04% | -52.91% +4.38% | -50.69% +39.29% | |
Revenue Growth | N/A N/A | N/A N/A | 229.22% N/A | N/A N/A | |
Current Ratio | 9.09 -18.59% | 11.16 -18.51% | 13.70 +46.67% | 9.34 -18.95% | |
Cash Ratio | 8.64 -16.78% | 10.38 -20.58% | 13.07 +50.30% | 8.70 -21.60% | |
Debt-to-Equity Ratio | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Debt-to-Assets Ratio | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow